A Randomized, Placebo-controlled Trial of Pre-treatment HPV Vaccination on Outcomes to LEEP Treatment of Cervical High Grade Squamous Intraepithelial Lesions in HIV-infected Women
Phase of Trial: Phase II
Latest Information Update: 08 May 2018
Price : $35 *
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Therapeutic Use
- 12 May 2016 Planned End Date changed from 1 Aug 2016 to 1 Mar 2017.
- 12 May 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016.
- 22 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.